NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that the Company will participate in the following upcoming events:
| EVENT: | Piper Sandler 37th Annual Healthcare Conference |
| DATE: | Wednesday, December 3, 2025 |
| TIME: | 11:30am ET |
| EVENT: | 2025 American Epilepsy Society Annual Meeting – Scientific Exhibit Session |
| DATE: | Sunday, December 7, 2025 |
| TIME: | 2pm – 5pm ET |
About Bright Minds Biosciences
Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients’ lives.
Bright Minds Biosciences has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.
Contact Information
Investor Relations
Lisa M. Wilson
T: 212-452-2793
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$64.25 |
| Daily Change: | -1.28 -1.95 |
| Daily Volume: | 763 |
| Market Cap: | US$455.530M |
November 06, 2025 October 30, 2025 September 04, 2025 September 04, 2025 August 25, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
